Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Prepaid Assets (2016 - 2025)

Historic Prepaid Assets for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $37.5 million.

  • Corcept Therapeutics' Prepaid Assets rose 9851.13% to $37.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.5 million, marking a year-over-year increase of 9851.13%. This contributed to the annual value of $21.9 million for FY2024, which is 2061.53% down from last year.
  • As of Q3 2025, Corcept Therapeutics' Prepaid Assets stood at $37.5 million, which was up 9851.13% from $24.0 million recorded in Q2 2025.
  • Corcept Therapeutics' Prepaid Assets' 5-year high stood at $39.6 million during Q1 2025, with a 5-year trough of $9.0 million in Q2 2021.
  • Its 5-year average for Prepaid Assets is $19.6 million, with a median of $18.9 million in 2024.
  • In the last 5 years, Corcept Therapeutics' Prepaid Assets skyrocketed by 12807.99% in 2022 and then plummeted by 2061.53% in 2024.
  • Corcept Therapeutics' Prepaid Assets (Quarter) stood at $10.3 million in 2021, then surged by 59.22% to $16.4 million in 2022, then soared by 67.82% to $27.6 million in 2023, then fell by 20.62% to $21.9 million in 2024, then soared by 71.25% to $37.5 million in 2025.
  • Its Prepaid Assets stands at $37.5 million for Q3 2025, versus $24.0 million for Q2 2025 and $39.6 million for Q1 2025.